Pioglitazone - A Bullet for Many Targets!

Published on:March 2018
Indian Journal of Pharmacy Practice, 2018; 11(1):3-6
Review Article | doi:10.5530/ijopp.11.1.2


Pioglitazone - A Bullet for Many Targets!


Authors and affiliation (s):

Deepalakshmi M, Haritha Atluri, Arun KP*

Department of Pharmacy Practice, JSS College of Pharmacy, JSS University, Ooty, Tamil Nadu, INDIA.

Abstract:

Obesity and aging has resulted ever increasing incidence of type 2 diabetes in many developing countries including India. Among the various classes of anti-diabetic agents including being used in the clinics, thiazolidinediones (TZDs) comprise important class which is Peroxisome Proliferator-Activated Receptor Gamma (PPARG) agonists. This article reviews the Pharmacology of Pioglitazone beyond its anti-diabetic effect. Thorough literature search was done including e-resources to understand the clinical evidences for the anti-diabetic and extra anti diabetic activities of Pioglitazone. Pioglitazone is known to successfully control the HbA1c levels not only in many patients with Type 2 diabetes but, also in pre-diabetic subjects. We generally use lower doses of Pioglitazone (about 30 mg) in India and so it will take longer time to reach the cumulative dose, and if use the dose of 7.5 mg, it would take even longer time close to 10 years. Thus, low dose Pioglitazone has been very widely used due to its efficacy and lower frequency of side effects including weight gain and fluid retention. It can be concluded that the literature evidences suggest that Pioglitazone has acceptable safety profile, many extra anti diabetic effects including cardiovascular and pleotropic effects apart from its use in Type 2 diabetes patients and pre-diabetic individuals.

Key words: Pioglitazone, PPARgamma agonists, Type 2 diabetes, Extra anti diabetic effect.




 

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmacy Practice (IJOPP) [ISSN-0974-8326] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.

DOI HISTORY

IJOPP uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2014 are being assigned DOIs for its permanent URLs